throbber
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
`(19) World Intellectual Property Organization
`International Bureau
`
`(43) International Publication Date
`29 August 2002 (29.08.2002)
`
`(10) International Publication Number
`
`WO 02/066019 A2
`
`(51) International Patent Classification7:
`
`A61K 31/00
`
`(21) International Application Number:
`
`PCT/EP02/01714
`
`(22) International Filing Date: 18 February 2()02 (1 8.()2.2()()2)
`
`(25) Filing Language:
`
`(26) Publication Language:
`
`English
`
`English
`
`(30) Priority Data:
`01040724
`01249572
`
`19 February 2001 (19.02.2001)
`17 October 2001 (17.10.2001)
`
`GB
`GB
`
`(71) Applicant (for all designated States except A]? US): NO-
`VARTIS AG [CH/CH]; Lichtstrasse 35, CH—4056 Basel
`(CH).
`
`(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN
`VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT];
`Brunner Strasse 59, A—l230 Vienna (AT).
`
`(72) Inventors; and
`LANE, Heidi
`(75) Inventors/Applicants (for US only):
`[CH/CH]; Lehenniattstr.
`189, CH—4052 Basel
`(CH).
`O’REILLY, Terence
`[CA/C11];
`l)raht7.ugstrasse 51,
`CH—4057 Basel
`(CH). WOOD, Jeanette, Marjorie
`
`[NZ/CH]; In den Kleematten 18, CH—4105 Biel—Benken
`(C11).
`
`Agent: BECKER, Konrad; Novartis AG, Corporate
`Intellectual Property, Patent & Trademark Department,
`CH—4002 Basel (CH).
`
`Designated States (national): AE, AG, AL, AM, AT, AU,
`AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
`CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
`HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
`LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH,
`PL, PT, RO. RU, SE, SG. SI, SK, TJ, TM, TN, TR, TT, UA,
`US, UZ, VN, YU, ZA, ZW.
`
`Designated States (regional): Eurasian patent (AM, AZ,
`BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
`CH, CY, DE, DK, ES, FT, FR, GB, GR, IE, IT, LU, MC,
`NL, PT, SE, TR).
`
`Published:
`without international search report and to be republished
`upon receipt ofthat report
`
`For two-letter codes and other abbreviations, refer to the ”Guid-
`ance /Votes on Codes and Abbreviations" appearing at the begin-
`ning ofeach regular issue ofthe PCT Gazette.
`
`O02/066019A2
`
`6.:5 :1 E 0>Z875 aaEZa
`
`(57) Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a
`chemotherapeutic agent.
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 001
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`Cancer Treatment
`
`The present invention relates to a new use, in particular a new use for a compound group
`
`comprising rapamycin and derivatives thereof.
`
`Rapamycin is a known macrolide antibiotic produced by Streptomyces
`
`hygroscopicus. Suitable derivatives of rapamycin include e.g. compounds of
`
`formula I
`
`wherein
`
`R1 is CH3 or C3.6alkynyl,
`
`R2 is H or -CH2-CH2-OH, and
`
`X is =0, (H,H) or (H,OH)
`
`provided that R2 is other than H when X is =0 and R1 is CH3.
`
`Compounds of formula I are disclosed e.g. in WO 94/09010, WO 95/16691 or WO 96/41807,
`
`which are incorporated herein by reference. They may be prepared as diclosed or by
`
`analogy to the procedures described in these references
`
`Preferred compounds are 32-deoxorapamycin, 16-pent-2-ynyloxy-32-deoxorapamycin, 16-
`
`pent-2-ynyloxy-32(8)-dihydro-rapamycin, 16—pent—2—ynyloxy-32(S)-dihydro-40—O—(2-
`
`hydroxyethyl)-rapamycin and, more preferably, 40-O-(2-hydroxyethyl)-rapamycin (referred
`
`thereafter as Compound A), disclosed as Example 8 in WO 94I09010.
`
`Compounds of formula I have, on the basis of observed activity, e.g. binding to
`
`macrophilin-12 (also known as FK—506 binding protein or FKBP-12), e.g. as described in WO
`
`94/09010, WO 95/16691 or WO 96141807, been found to be useful e.g. as
`
`immunosuppressant, e.g. in the treatment of acute allograft rejection. It has now been found
`
`that Compounds of formula I have potent antiproliferative properties which make them useful
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 002
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`for cancer chemotherapy, particularly of solid tumors, especially of advanced solid tumors.
`
`There is still the need to expand the armamentarium of cancer treatment of solid tumors,
`
`especially in cases where treatment with anticancer compounds is not associated with
`
`disease regression or stabilization.
`
`In accordance with the particular findings of the present invention, there is provided:
`
`1.1 A method for treating solid tumors in a subject in need thereof, comprising
`
`administering to said subject a therapeutically effective amount of a compound of
`
`formula I.
`
`A method for inhibiting growth of solid tumors in a subject in need thereof, comprising
`
`administering to said subject a therapeutically effective amount of a compound of
`
`formula I.
`
`A method for inducing tumor regression, e.g. tumor mass reduction, in a subject in
`
`need thereof, comprising administering to said subject a therapeutically effective
`
`amount of a compound of formula I.
`
`A method for treating solid tumor invasiveness or symptoms associated with such
`
`tumor growth in a subject in need thereof, comprising administering to said subject a
`
`therapeutically effective amount of a compound of formula I.
`
`A method for preventing metastatic spread of tumours or for preventing or inhibiting
`
`growth of micrometastasis in a subject in need thereof, comprising administering to
`
`said subject a therapeutically effective amount of a compound of formula I.
`
`By "solid tumors” are meant tumors and/or metastasis (whereever located) other than
`
`lymphatic cancer, e.g. brain and other central nervous system tumors (eg. tumors of the
`
`meninges, brain, spinal cord, cranial nerves and other parts of central nervous system, e.g.
`
`glioblastomas or medulla blastomas); head and/or neck cancer; breast tumors; circulatory
`
`system tumors (e.g. heart, mediastinum and pleura, and other intrathoracic organs, vascular
`
`tumors and tumor-associated vascular tissue); excretory system tumors (e.g. kidney. renal
`
`pelvis, ureter, bladder, other and unspecified urinary organs); gastrointestinal tract tumors
`
`(e.g. oesophagus, stomach, small intestine, colon, colorectal, rectosigmoid junction, rectum,
`
`anus and anal canal), tumors involving the liver and intrahepatic bile ducts, gall bladder,
`
`other and unspecified parts of biliary tract, pancreas, other and digestive organs); head and
`
`neck; oral cavity (lip, tongue, gum, floor of mouth, palate, and other parts of mouth, parotid
`
`gland, and other parts of the salivary glands, tonsil, oropharynx, nasopharynx, pyriforrn
`
`sinus, hypopharynx. and other sites in the lip, oral cavity and pharynx); reproductive system
`
`tumors (e.g. vulva, vagina, Cervix uteri, Corpus uteri, uterus, ovary, and other sites
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 003
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`associated with female genital organs, placenta, penis, prostate, testis, and other sites
`
`associated with male genital organs); respiratory tract tumors (e.g. nasal cavity and middle
`
`ear, accessory sinuses, larynx, trachea, bronchus and lung, e.g. small cell lung cancer or
`
`non-small cell lung cancer); skeletal system tumors (e.g. bone and articular cartilage of
`
`limbs, bone articular cartilage and other sites); skin tumors (e.g. malignant melanoma of the
`
`skin, non-melanoma skin cancer, basal cell carcinoma of skin, squamous cell carcinoma of
`
`skin, mesothelioma, Kaposi’s sarcoma); and tumors involving other tissues incluing
`
`peripheral nerves and autonomic nervous system, connective and soft tissue,
`
`retroperitoneum and peritoneum, eye and adnexa, thyroid, adrenal gland and other
`
`endocrine glands and related structures, secondary and unspecified malignant neoplasm of
`
`lymph nodes, secondary malignant neoplasm of respiratory and digestive systems and
`
`secondary malignant neoplasm of other sites.
`
`Where hereinbefore and subsequently a tumor, a tumor disease, a carcinoma or a cancer is
`
`mentioned, also metastasis in the original organ or tissue and/or in any other location are
`
`implied alternatively or in addition, whatever the location of the tumor and/or metastasis is.
`
`in a series of further specific or alternative embodiments, the present invention also provides
`
`1.6 A method for the treatment of a disease associated with deregulated angiogenesis in a
`
`subject in need thereof, comprising administering to said subject a therapeutically
`
`effective amount of rapamycin or a derivative thereof, e.g. CCl779, ABT578 or a
`
`compound of formula I.
`
`A method for inhibiting or controlling deregulated angiogenesis in a subject in need
`
`thereof, comprising administering to said subject a therapeutically effective amount of
`
`rapamycin or a derivative thereof, e.g. CCl779, ABT578 or a compound of formula I.
`
`A method for enhancing the activity of a chemotherapeutic agent or for overcoming
`
`resistance to a chemotherapeutic agent in a subject in need thereof, comprising
`
`administering to said subject a therapeutically effective amount of rapamycin or a
`
`derivative thereof, e.g. CCl779, ABT578 or a compound of formula l, either
`
`concomitantly or sequentially with said chemotherapeutic agent.
`
`A method according to 1.8 wherein the chemotherapeutic agent is an inhibitor of signal
`
`transduction pathways directed either against host cells or processes involved in tumor
`
`formation and/or metastases formation or utilised by tumour cells for proliferation,
`
`survival, differentiation or development of drug resistance.
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 004
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`-4-
`
`1.10 A method as indicated above, wherein rapamycin or a derivative thereof, e.g. CCl779,
`
`ABT578 or a compound of formula I is administered intermittently.
`
`CCl779 is a rapamycin derivative, i.e. 40- [3-hydroxy-2-(hydroxymethyl)-2-methylpropa-
`
`noate]-rapamycin or a pharmaceutically acceptable salt thereof, and is disclosed e.g. in USP
`
`5,362,718. ABT578 is a 40-substituted rapamycin derivative further comprising a diene
`
`reduction.
`
`Examples of diseases associated with deregulated angiogenesis include without limitation
`
`e.g. neoplastic diseases, e.g. solid tumors. Angiogenesis is regarded as a prerequisite for
`
`those tumors which grow beyond a certain diameter, e.g. about 1-2 mm.
`
`In a series of further specific or alternative embodiments, the present invention also
`
`provides:
`
`2.1 A compound of formula I for use in any method as defined under 1.1 to 1.5 above.
`
`2.2 Rapamycin or a derivative thereof, e.g. CCl779, ABT578 or a compound of formula I
`
`for use in any method as defined under 1.6 to 1.10 above or 7 below.
`
`3.1 A compound of formula I for use in the preparation of a pharmaceutical composition for
`
`use in any method as defined under 1.1 to 1.5 above.
`
`3.2 Rapamycin or a derivative thereof, e.g. CCl779, ABT578 or a compound of formula I
`
`for use in the preparation of a pharmaceutical composition for use in any method as
`
`defined under 1.6 to 1.10 above or 7 below.
`
`A pharmaceutical composition for use in any method as defined under 1.1 to 1.5 above
`
`comprising a compound of formula I together with one or more pharmaceutically
`
`acceptable diluents or carriers therefor.
`
`A pharmaceutical composition for use in any method as defined under 1.6 to 1.10
`
`above or 7 below comprising rapamycin or a der'n/ative thereof, e.g. CCI779, ABT578
`
`or a compound of formula I, e.g. Compound A, together with one or more
`
`pharmaceutically acceptable diluents or carriers therefor.
`
`A pharmaceutical combination "comprising a) a first agent which is rapamycin or a
`
`derivative thereof, e.g. CCl779, ABT578 or a compound of formula I, e.g. Compound
`
`A, and b) a co-agent which is a chemotherapeutic agent, e.g. as defined hereinafter.
`
`A pharmaceutical combination comprising an amount of a) a first agent which is
`
`rapamycin or a derivative thereof, e.g. CCI779, ABT578 or a compound of formula I,
`
`e.g. Compound A, and b) a co-agent which is a chemotherapeutic agent selected from
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 005
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`the compounds defined under paragraph (iv) or (v) below, to produce a synergistic
`
`therapeutic effect.
`
`A method as defined above comprising co-administration, e.g. concomitantly or in
`
`sequence, of a therapeutically effective amount of rapamycin or a derivative thereof,
`
`e.g. CCl779, ABT578 or a compound of formula l, e.g. Compound A, and a second
`
`drug substance, said second drug substance being a chemotherapeutic agent, e.g. as
`
`indicated hereinafter.
`
`A method for treating post-transplant lymphoproliferative disorders or a lymphatic
`
`cancer, e.g. for treating tumor invasiveness or symptoms associated with such tumor
`
`growth in a subject in need thereof, comprising co-administering to said subject, e.g.
`
`concomitantly or in sequence, of rapamycin or a derivative thereof, e.g. CCl779,
`
`ABT578 or a compound of formula I, e.g. Compound A, and a second drug substance,
`
`said second drug substance being a chemotherapeutic agent, e.g. as indicated
`
`hereinafter.
`
`By “lymphatic cancer” are meant e.g. tumors of blood and lymphatic system (e.g. Hodgkin's
`
`disease, Non-Hodgkin's lymphoma, Burkitt’s lymphoma, AlDS—related lymphomas, malignant
`
`immunoproliferative diseases, multiple myeloma and malignant plasma cell neoplasms,
`
`lymphoid leukemia, myeloid leukemia, acute or chronic lymphocytic leukemia, monocytic
`
`leukemia, other leukemias of specified cell type, leukemia of unspecified cell type, other and
`
`unspecified malignant neoplasms of lymphoid, haematopoietic and related tissues, for
`
`example diffuse large cell lymphoma, T-cell lymphoma or cutaneous T-cell lymphoma).
`
`By the term “chemotherapeutic agent” is meant especially any chemotherapeutic agent other
`
`than rapamycin or a derivative thereof. it includes but is not limited to,
`
`i.
`
`ii.
`
`an aromatase inhibitor,
`
`an antiestrogen, an anti-androgen (especially in the case of prostate cancer) or a
`
`gonadorelin agonist,
`
`a topoisomerase I inhibitor or a topoisomerase II inhibitor,
`
`a microtubule active agent, an alkylating agent, an antineoplastic antimetabolite or a
`
`platin compound,
`
`a compound targeting/decreasing a protein or lipid kinase activity or a protein or lipid
`
`phosphatase activity, a further anti-angiogenic compound or a compound which
`
`induces cell differentiation processes,
`
`a bradykinin 1 receptor or an angiotensin II antagonist,
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 006
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`a cyclooxygenase inhibitor, a bisphosphonate, a histone deacetylase inhibitor, a
`
`heparanase inhibitor (prevents heparan sulphate degradation), e.g. Pl-88, a biological
`
`response modifier, preferably a Iymphokine or interferons, e.g. interferon 7, an
`
`ubiquitination inhibitor, or an inhibitor which blocks anti-apoptotic pathways,
`
`an inhibitor of Ras oncogenic isoforms, e.g. H-Ras, K-Ras or N-Ras, or a farnesyl
`
`transferase inhibitor, e.g. L-744,832 or DK8G557,
`
`a telomerase inhibitor, e.g. telomestatin,
`
`a protease inhibitor, a matrix metalloproteinase inhibitor, a methionine aminopeptidase
`
`inhibitor, e.g. bengamide or a derivative thereof, or a proteosome inhibitor, e.g.
`PS-341.
`
`The term “aromatase inhibitor” as used herein relates to a compound which inhibits the
`
`estrogen production, i.e. the conversion of the substrates androstenedione and testosterone
`
`to estrone and estradiol, respectively. The term includes, but is not limited to steroids,
`
`especially atamestane, exemestane and formestane and, in particular, non—steroids,
`
`especially aminoglutethimide, roglethimide, pyridoglutethimide, trilostane, testolactone,
`
`ketokonazole, vorozole, fadrozole, anastrozole and letrozole. Exemestane can be
`
`administered, e.g., in the form as it is marketed, e.g. under the trademark AROMASINTM.
`
`Formestane can be administered, e.g., in the form as it is marketed, e.g. under the
`
`trademark LENTARONTM. Fadrozole can be administered, e.g., in the form as it is marketed,
`
`e.g. under the trademark AFEMATM. Anastrozole can be administered, e.g., in the form as it
`
`is marketed, e.g. under the trademark ARIMIDEXTM. Letrozole can be administered, e.g., in
`
`the form as it is marketed, e.g. under the trademark FEMARATM or FEMARTM
`
`Aminoglutethimide can be administered, e.g., in the form as it is marketed, e.g. under the
`
`trademark ORlMETENTM. A combination of the invention comprising a chemotherapeutic
`
`agent which is an aromatase inhibitor is particularly useful for the treatment of hormone
`
`receptor positive tumors, e.g. breast tumors.
`
`The term “antiestrogen” as used herein relates to a compound which antagonizes the effect
`
`of estrogens at the estrogen receptor level. The term includes, but is not limited to
`
`tamoxifen, fulvestrant, raloxifene and raloxifene hydrochloride. Tamoxifen can be
`
`administered, e.g., in the fonn as it is marketed, e.g. under the trademark NOLVADEXTM.
`
`Raloxifene hydrochloride can be administered, e.g., in the form as it is marketed, e.g. under
`
`the trademark EVISTATM. Fulvestrant can be formulated as disclosed in US 4,659,516 or it
`
`can be administered, e.g., in the form as it is marketed, e.g. under the trademark
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 007
`
`

`
`W0 02/066019
`
`PCT/EP02/01714_
`
`FASLODEXTM. A combination of the invention comprising a chemotherapeutic agent which is
`
`an antiestrogen is particularly useful for the treatment of estrogen receptor positive tumors,
`
`e.g. breast tumors.
`
`The term “anti—androgen" as used herein relates to any substance which is capable of
`
`inhibiting the biological effects of androgenic hormones and includes, but is not limited to,
`
`bicalutamide (CASODEXTM), which can be formulated, e.g. as disclosed in US 4,636,505.
`
`The term “gonadorelin agonist” as used herein includes, but is not limited to abarelix,
`
`goserelin and goserelin acetate. Goserelin is disclosed in US 4,100,274 and can be
`
`administered, e.g., in the form as it is marketed, e.g. under the trademark ZOLADEXTM.
`
`Abarelix can be formulated, eg. as disclosed in US 5,843,901.
`
`The term “topoisomerase l inhibitor” as used herein includes, but is not limited to topotecan,
`
`irinotecan, 9-nitrocamptothecin and the macromolecular camptothecin conjugate PNU-
`
`166148 (compound A1 in W099/17804). lrinotecan can be administered, e.g. in the form as
`
`it is marketed, e.g. under the trademark CAMPTOSARTM. Topotecan can be administered,
`
`e.g., in the form as it is marketed, e.g. under the trademark HYCAMTINTM.
`
`The term ‘‘topoisomerase II inhibitor’ as used herein includes, but is not limited to the
`
`anthracyclines such as doxorubicin (including liposomal formulation, e.g. CAELYXTM),
`
`daunorubicin, epirubicin, idarubicin and nemorubicin, the anthraquinones mitoxantrone and
`
`losoxantrone, and the podophillotoxines etoposide and teniposide.’ Etoposide can be
`
`administered, e.g. in the form as it is marketed, e.g. under the trademark ETOPOPHOSTM.
`
`Teniposide can be administered, e.g. in the form as it is marketed, e.g. under the trademark
`
`VM 26-BRISTOLTM Doxorubicin can be administered, e.g. in the form as it is marketed, e.g.
`
`under the trademark ADRIBLASTINTM. Epirubicin can be administered, e.g. in the form as it
`
`is marketed, e.g. under the trademark FARMORUBICINTM. idarubicin can be administered,
`
`e.g. in the form as it is marketed, e.g. under the trademark ZAVEDOSTM. Mitoxantrone can
`
`be administered, e.g. in the form as it is marketed, e.g. under the trademark
`
`NOVANTRONTM.
`
`The term “microtubule active agent” relates to microtubule stabilizing and microtubule
`
`destabilizing agents including, but not limited to taxanes, e.g. paclitaxel and docetaxel, vinca
`
`alkaloids, e.g., vinblastine, especially vinblastine sulfate, vincristine especially vincristine
`
`sulfate, and vinorelbine, discodennolides and epothilones and derivatives thereof, e.g.
`
`epothilone B or a derivative thereof. Paclitaxel may be administered e.g. in the form as it is
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 008
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`-3-
`
`marketed, e.g. TAXOLTM. Docetaxel can be administered, e.g., in the form as it is marketed,
`
`e.g. under the trademark TAXOTERETM. Vinblastine sulfate can be administered, e.g., in the
`
`form as it is marketed, e.g. under the trademark VlNBLASTlN R.P.TM. Vincristine sulfate can
`be administered, e.g., in the form as it is marketed, e.g. under the trademark FARMISTINTM.
`
`Discodermoiide can be obtained, e.g., as disclosed in US 5,010,099.
`
`The term “alkylating agent" as used herein includes, but is not limited to cyclophosphamide,
`
`ifosfamide, melphalan or nitrosourea (BCNU or Gliade
`
`ITM). Cyclophosphamide can be
`
`administered, e.g., in the form as it is marketed, e.g. under the trademark CYCLOSTINTM.
`
`Ifosfamide can be administered, e.g., in the form as it is marketed, e.g. under the trademark
`
`HOLOXANT“.
`
`The term “antineoplastic antimetabolite” includes, but is not limited to 5-fluorouracil,
`
`capecitabine, gemcitabine, methotrexate and edatrexate. Capecitabine can be administered.
`
`e.g., in the form as it is marketed, e.g. under the trademark XELODATM. Gemcitabine can be
`
`administered, e.g., in the form as it is marketed, e.g. under the trademark GEMZARTM.
`
`The term “platin compound” as used herein includes, but is not limited to carboplatin, cis-
`
`platin and oxaliplatin. Carboplatin can be administered, e.g., in the form as it is marketed,
`
`e.g. under the trademark CARBOPLATN. Oxaliplatin can be administered, e.g., in the form
`
`as it is marketed, e.g. under the trademark ELOXATINTM.
`
`The term “compounds targeting/decreasing a protein or lipid kinase activity or further anti-
`
`A
`
`angiogenic compounds” as used herein includes, but is not limited to protein tyrosine kinase
`
`and/or serine and/or threonine kinase inhibitors or lipid kinase inhibitors, e.g. compounds
`
`targeting, decreasing or inhibiting the activity of the epidermal growth factor family of
`
`receptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- or heterodimers), the
`
`vascular endothelial growth factor family of receptor tyrosine kinases (VEGFR), the platelet-
`
`derived growth factor~receptors (PDGFR), the fibroblast growth factor~receptors (FGFR), the
`
`insulin-like growth factor receptor 1 (IGF-1R), the Trk receptor tyrosine kinase family, the Axl
`
`receptor tyrosine kinase family, the Ret receptor tyrosine kinase, the Kit/SCFR receptor
`
`tyrosine kinase, members of the c-Abl family and their gene-fusion products (e.g. BCR-Abl),
`
`members of the protein kinase C (PKC) and Raf family of serine/threonine kinases,
`
`members of the MEK, SRC, JAK, FAK, PDK or Pl(3) kinase family, or of the Pl(3)-kinase-
`
`related kinase family, and/or members of the cyclin-dependent kinase family (CDK) and anti-
`
`angiogenic compounds having another mechanism for their activity, e.g. unrelated to protein
`
`or lipid kinase inhibition.
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 009
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`Compounds which target, decrease or inhibit the activity of VEGFR are especially
`
`compounds, proteins or antibodies which inhibit the VEGF receptor tyrosine kinase, inhibit a
`
`VEGF receptor or bind to VEGF, and are in particular those compounds, proteins or
`
`monoclonal antibodies generically and specifically disclosed in W0 98/35958, e.g. 1-(4-
`
`chloroanilino)—4-(4-pyridylmethyl)phthalazine or a pharmaceutically acceptable salt thereof,
`
`e.g. the succinate, or in W0 00/09495, W0 00/27820, WO O0/59509, W0 98/11223, W0
`
`00/27819 and EP 0 769 947; those as described by M. Prewett et al in Cancer Research 59
`
`(1999) 5209-5218, by F. Yuan et al in Proc. Natl. Acad. Sci. USA, vol. 93, pp. 14765-14770,
`
`Dec. 1996, by Z. Zhu et al in Cancer Res. 58, 1998, 3209-3214, and by J. Mordenti et al in
`
`Toxicologic Pathology, Vol. 27, no. 1, pp 14-21, 1999; in W0 00l37502 and W0 94/10202;
`
`Angiostatinm, described by M. s. 0’Reil|y et al, Cell 79, 1994, 315-328; Endostatinm,
`
`described by M. S. 0‘Reilly et al, Cell 88, 1997, 277-285; anthranilic acid amides; ZD4190;
`
`ZD6474; SU5416; SU6668; or anti-VEGF antibodies or anti-VEGF receptor antibodies,e.g.
`
`RhuMab.
`
`By antibody is meant intact monoclonal antibodies, polyclonal antibodies, multispecific
`
`antibodies formed from at least 2 intact antibodies, and antibodies fragments so long as they
`
`exhibit the desired biological activity.
`
`Compounds which target, decrease or inhibit the activity of the epidermal growth factor
`
`receptor family are especially compounds, proteins or antibodies which inhibit members of
`
`the EGF receptor tyrosine kinase family, e.g. EGF receptor, ErbB2, ErbB3 and ErbB4 or bind
`
`to EGF or EGF related ligands, and are in particular those compounds, proteins or
`
`monoclonal antibodies generically and specifically disclosed in W0 97/02266, e.g. the
`
`compound of ex. 39, or in EP 0 564 409, W0 99/03854, EP 0520722, EP 0 566 226, EP 0
`
`787 722, EP 0 837 063, US 5,747,498, WO 98/10767, W0 97/30034, WO 97/49688, WO
`
`97/38983 and, especially, W0 96/30347 (e.g. compound known as CP 358774), WO
`
`96133980 (e.g. compound ZD 1839) and W0 95/03283 (e.g. compound ZM105180); e.g.
`
`trastuzumab (HerpetinR), oetuximab, lressa, 0Sl-774, Cl-1033, EKB-569, GW-2016, E1.1,
`
`E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 or E7.6.3.
`
`Compounds which target, decrease or inhibit the activity of PDGFR are especially
`
`compounds which inhibit the PDGF receptor, e.g. a N-phenyl-2-pyrimidine-amine derivative,
`
`e.g. imatinib.
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 010
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`Compounds which target, decrease or inhibit the activity of c-Abl family members and their
`
`gene fusion products, e.g. a N—phenyl-2-pyrimidine-amine derivative, e.g. imatinib;
`
`PD180970; AG957; or NSC 680410.
`
`Compounds which target, decrease or inhibit the activity of protein kinase C, Raf, MEK,
`
`SRC, JAK, FAK and PDK family members, or Pl(3) kinase or P|(3) kinase—related family
`
`members, and/or members of the cyclin-dependent kinase family (CDK) are especially those
`
`staurosporine derivatives disclosed in EP 0 296 110, e.g. midostaurin; examples of further
`
`compounds include e.g. UCN-01, safingol, BAY 43-9006, Bryostatin 1, Perifosine;
`
`llmofosine; R0 318220 and R0 320432; GO 6976; lsis 3521; or LY333531/LY379196.
`
`Further anti-angiogenic compounds are e.g. thalidomide (THALOMID) and TNP-470.
`
`Compounds which target, decrease or inhibit the activity of a protein or lipid phosphatase are
`
`e.g. inhibitors of phosphatase 1, phosphatase 2A, PTEN or CDC25, e.g. okadaic acid or a
`
`derivative thereof.
`
`Compounds which induce cell differentiation processes are e.g. retinoic acid, ot—, 7» or 8-
`
`tocopherol or or—, 7- or 8-tocotrienol.
`
`The term cyclooxygenase inhibitor as used herein includes, but is not limited to, e.g.
`
`celecoxib (CelebrexR), rofecoxib (Vio>o<R), etoricoxib, valdecoxib or a 5-alkyl-2-
`
`arylaminophenylacetic acid, e.g. 5~methyl-2-(2'-chloro-6’-fluoroani|ino)pheny| acetic acid.
`
`The term “histone deacetylase inhibitor” as used herein includes, but is not limited to MS-27-
`
`275, SAHA, pyroxamide, FR-901228 or valproic acid.
`
`The term “bisphosphonates” as used herein includes, but is not limited to, etridonic,
`
`clodronic, tiludronic, pamidronic, alendronic, ibandronic, risedronic and zoledronic acid.
`
`“Etridonic acid” can be administered, e.g., in the form as it is marketed, e.g. under the
`
`trademark DIDRONELTM. “Clodronic acid” can be administered, e.g., in the form as it is
`
`marketed, e.g. under the trademark BONEFOSTM. “Tiludronic acid” can be administered,
`
`e.g., in the form as it is marketed, e.g. under the trademark SKELIDTM. “Pamidronic acid”
`
`can be administered, e.g. in the form as it is marketed, e.g. under the trademark AREDIATM.
`
`“Alendronic acid” can be administered, e.g., in the form as it is marketed, e.g. under the
`
`trademark FOSAMAXTM. “lbandronic acid” can be administered, e.g., in the fonfn as it is
`
`marketed, e.g. under the trademark BONDRANATTM. “Risedronic acid” can be administered,
`
`e.g., in the form as it is marketed, e.g. under the trademark ACTONELTM. “Zoledronic acid”
`
`can be administered, e.g. in the form as it is marketed, e.g. under the trademark ZOMETATM
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 011
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`The term “matrix metalloproteinase inhibitor” as used herein includes, but is not limited to
`
`collagen peptidomimetic and nonpetidomimetic inhibitors, tetracycline derivatives, e.g.
`
`hydroxamate peptidomimetlc inhibitor batimastat and its orally bioavailable analogue
`
`marimastat, prinomastat, BMS-279251, BAY 12-9566, TAA211 or AAJ996.
`
`In each case where citations of patent applications or scientific publications are given, the
`
`subject-matter relating to the compounds is hereby incorporated into the present application
`
`by reference. Comprised are likewise the pharmaceutically acceptable salts thereof, the
`
`corresponding racemates, diastereoisomers, enantiomers, tautomers as well as the
`
`corresponding crystal modifications of above disclosed compounds where present, e.g.
`
`solvates, hydrates and polymorphs, which are disclosed therein. The compounds used as
`
`active ingredients in the combinations of the invention can be prepared and administered as
`
`described in the cited documents, respectively. Also within the scope of this invention is the
`
`combination of more than two separate active ingredients as set forth above, i.e. a
`
`pharmaceutical combination within the scope of this invention could include three active
`
`ingredients or more. Further both the first agent and the co-agent are not the identical
`
`ingredient.
`
`Utility of the compounds of formula I in treating solid tumors as hereinabove specified, may
`
`be demonstrated in animal test methods as well as in clinic, for example in accordance with
`
`the methods hereinafter described.
`
`A.
`
`In Vitro
`
`A.1 Antiproliferative activity in combination with other agents
`
`A cell line, e.g. the compound A resistant A549 line (lC5o in low nM range) versus the
`
`comparative Compound A resistant KB-31 and HCT116 lines (|C5o in the uM range), is added
`
`to 96-well plates (1,500 oells/well in 100 pl medium) and incubated for 24 hr. Subsequently, a
`
`two-fold dilution series of each compound (Compound of formula I or a known
`
`chemotherapeutic agent) is made in separate tubes (starting at 8 x the lC5o of each
`
`compound) either alone or in paired combinations, and the dilutions are added to the wells.
`
`The cells are then re-incubated for 3 days. Methylene blue staining is performed on day 4
`
`and the amount of bound dye (proportional to the number of surviving cells that bind the dye)
`
`determined. lC5os are subsequently determined using the Calcusyn program, which provides
`
`a measure of the interaction, namely the so-called non-exclusive combination index (Cl),
`
`where: Cl ~ 1 = the interaction is nearly additive; 0.85 — 0.9 = slight synergism; < 0.85 =
`
`synergy. In this assay, the compounds of formula I show interesting antiproliferatlve activity
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 012
`
`

`
`W0 02/066019
`
`PCT/EP02/01714
`
`in combination with another chemotherapeutic agent. For example the following CI values
`
`are obtained with a combination of Compound A and cisplatinum, paclitaxel, gemcitabine and
`
`doxorubicin, showing synergistic effects.
`
`Cl
`
`Cell line
`
`Cisplatinum
`
`Paclitaxel
`
`Gemcitabine
`
`Doxorubicin
`
`KB-31
`
`A549
`
`0.74
`
`0.47
`
`HCT116
`
`0.47
`
`0.9
`
`.
`
`.
`
`0.79
`
`0.76
`
`0.9
`
`0.7
`
`Furthermore, in this assay, Compound A potentiates the loss of A549 cell viability and cell
`
`death when it is used in combination with gemcitabine.
`
`A.2 Antiangiogenic activity
`
`In vitro assay of the antiproliferative activity of rapamycin or a derivative thereof, e.g.
`
`Compound A, against human umbilical vein endothelial cells (HUVECs) demonstrates lC5o
`
`values of 120 1 22 pM and 841 1 396, and > 10 000 pM for VEGF- and bFGF- and FBS-
`
`stimulated proliferation, respectively. Additionally, no significant effects of Compound A on
`
`bFGF-stimulated normal human dermal fibroblast (NHDF) proliferation are observed over the
`
`same concentration range. These results indicate that Compound A inhibits the proliferation
`
`of HUVECs, being particularly potent against the VEGF-induced proliferation, VEGF being a
`
`key pro-angiogenic factor.
`
`B.
`
`In Vivo
`
`In the following assays, antitumor activity is expressed as T/C% (mean increase in tumor
`
`volumes of treated animals divided by the mean increase of tumor volumes of control
`
`animals multiplied by 100) and % regressions (tumor volume minus initial tumor volume
`
`divided by the initial tumor volume and multiplied by 100).
`
`B.1 Activity in A549 human lung tumor xenografts
`
`Fragments of A549 tumors (approx. 25 mg; derived from Cell line CCL 185, ATCC,
`
`Rockville MD, USA) are transplanted subcutaneously into the left flank of BALB/c nude mice.
`
`Treatment is started on day 7 or day 12 following tumor transplantation. The compound to be
`
`tested is administered p.o. once per day from day 7/12 to day 38/55, respectively. In this
`
`Par Pharm., Inc.
`Exhibit 1055
`Page 013
`
`

`
`W0 02/066019
`
`PCT/

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket